BackgroundHuman epidermal growth factor receptor 2 (HER-2) amplification has been identified in approximately 3% of patients with metastatic colorectal cancer (mCRC). Owing to the lack of established anti-ERBB2 therapeutic approaches. mCRC patients with Her-2 amplification rarely receive targeted treatments. Moreover. https://www.aitsglobal.com/product-category/%d7%99%d7%9c%d7%93%d7%99%d7%9d/